Hypertension 2025 Scientific Sessions  /  Concurrent C: GLP1 and SGLT-2 and Hypertension  /  SGLT2 Inhibitors and GLP-1 Receptor Agonists at the Intersection of Kidney and Cardiovascular Disease
Logo

American Heart Association

  85
  0

Final ID:

SGLT2 Inhibitors and GLP-1 Receptor Agonists at the Intersection of Kidney and Cardiovascular Disease

  • Edmonston, Daniel  ( Duke Clinical Research Institute , Durham , North Carolina , United States )
    • Author Disclosures:
    Daniel Edmonston: DO NOT have relevant financial relationships
Meeting Info:

Hypertension 2025 Scientific Sessions

2025

Baltimore, Maryland

Session Info:

Concurrent C: GLP1 and SGLT-2 and Hypertension

Saturday, 09/06/2025 , 10:30AM - 12:00PM

Oral Abstract Session

More abstracts on this topic:
Comparative Antihypertensive Effects of Emerging Cardiorenal Therapies in Chronic Kidney Disease: A Network Meta-Analysis of SGLT2 Inhibitors, MRAs, and GLP-1 Receptor Agonists

Sabesan Vaishnavi, Prabakar Deipthan, Ravikumar Jayashree, Del Real Azucena

Right Heart, Right Drug: Sodium-Glucose Co-Transporter 2 Inhibitors in Pulmonary Hypertension: Reduced Mortality and Heart Failure Outcomes In a Large Propensity-Matched Cohort

Salih Rayan, Ahmed Sana, Bhushan Sheena, Mahmood Riaz, Umana Idopise, Egolum Ugochukwu

More abstracts from these authors:
Glucagon-like Peptide-1 Receptor Agonist Use and Cardiac Outcomes in Patients with End Stage Kidney Disease

Catanese Benjamin, Miller Cameron, Wolf Myles, Edmonston Daniel

You have to be authorized to contact abstract author. Please, Login
Not Available